Open an account

International Stem Cell

ISCO · OTC

$0.26−$0.023 (−8.13%)TodayMarket closed ·
Prev close $0.283

About ISCO

International Stem Cell Corp. operates as a research and development company for the therapeutic market. The company is headquartered in San Diego, California and currently employs 33 full-time employees. The company went IPO on 2006-09-25. The firm is primarily a research and development company for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The firm's products are based on human cell culture and types of pluripotent stem cells and hpSCs. The firm's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.

Employees
33
Headquarters
San Diego, California
Listed
Sep 25, 2006
Sector
Health Care
Industry
Biotechnology
Website
internationalstemcell.com

ISCO key statistics

Market cap
2.08M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
12.99K
Volume
26.38K
Open price
$0.29
High today
$0.29
Low today
$0.26
52 Week high
$0.54
52 Week low
$0.117

International Stem Cell (ISCO) at a glance

As of Oct 20, 2026, International Stem Cell (ISCO) shares are priced at $0.26, giving the company a market cap of 2.08M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.26 and $0.29. The current price is 0.0% above the day's low and 10.3% below its high.

Volume so far is 26.38K shares, above the average of 12.99K shares a day.

Over the past year International Stem Cell has ranged from $0.117 to $0.54, and now sits 34% of the way up that range.

International Stem Cell met or beat analyst EPS estimates in 2 of the last 2 quarters. In Q3 FY14 it reported -$1.50 per share against an estimate of -$1.53.

ISCO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 2 quarters, by 2.0% on average.

  1. Q2 FY14: reported -$1.50 per share against an estimate of -$1.53
  2. Q3 FY14: reported -$1.50 per share against an estimate of -$1.53

ISCO news

  • Press releaseACCESS Newswire

    International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results

Similar companies

Companies in the same industry as International Stem Cell

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.